Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Phone+1-408-5414191
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees1,700
OptionableNot Optionable
Cepheid (NASDAQ:CPHD) Frequently Asked Questions
What is Cepheid's stock symbol?
Cepheid trades on the NASDAQ under the ticker symbol "CPHD."
How were Cepheid's earnings last quarter?
Cepheid (NASDAQ:CPHD) posted its quarterly earnings data on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. The company's revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) earnings per share. View Cepheid's Earnings History.
Has Cepheid been receiving favorable news coverage?
Headlines about CPHD stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cepheid earned a news impact score of -2.5 on InfoTrie's scale. They also assigned media coverage about the scientific and technical instruments company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Cepheid?
Shares of CPHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cepheid's official website?
How can I contact Cepheid?
Cepheid's mailing address is 904 E Caribbean Dr, SUNNYVALE, CA 94089-1189, United States. The scientific and technical instruments company can be reached via phone at +1-408-5414191.
MarketBeat Community Rating for Cepheid (NASDAQ CPHD)
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe CPHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
